Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: A marriage under the arch of systems pharmacology

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 1, 2012, Pages 50-61

  Rostami Hodjegan, A ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BARIATRIC SURGERY; BILIARY CLEARANCE; CLEARANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; HUMAN; IN VITRO IN VIVO EXTRAPOLATION; KIDNEY CLEARANCE; LIVER CLEARANCE; PHYSIOLOGICALLY BASED PHARMACOKINETICS; PRIORITY JOURNAL; SIMULATION; SYSTEMS BIOLOGY;

COMPUTER SIMULATION; DRUG APPROVAL; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGICAL PROCESSES; PHARMACOLOGY, CLINICAL; RISK ASSESSMENT; SYSTEMS BIOLOGY;

EID: 84862619047     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.65     Document Type: Article

References (76)

1. Teorell, T. Studies on the diffusion effect upon ionic distribution: II. experiments on ionic accumulation. J. Gen. Physiol. 21, 107-122 (1937).
2. Paalzow, L.K. Torsten Teorell, the father of pharmacokinetics. Ups. J. Med. Sci. 100, 41-46 (1995).
3. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011).
4. Bouzom, F., Ball, K., Perdaems, N. & Walther, B. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm. Drug Dispos. 33, 55-71 (2012).
5. Chen, Y., Jin, J.Y., Mukadam, S., Malhi, V. & Kenny, J.R. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm. Drug Dispos. 33, 85-98 (2012).
6. Grillo, J.A. et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm. Drug Dispos. 33, 99-110 (2012).
7. Shaffer, C.L., Scialis, R.J., Rong, H. & Obach, R.S. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events. Biopharm. Drug Dispos. 33, 72-84 (2012).
8. Sinha, V.K., Snoeys, J., Osselaer, N.V., Peer, A.V., Mackie, C. & Heald, D. From preclinical to human-prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm. Drug Dispos. 33, 111-121 (2012).
9. Rowland, M., Peck, C. & Tucker, G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45-73 (2011).
10. J ohnson, T.N. & Rostami-Hodjegan, A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr. Anaesth. 21, 291-301 (2011).
11. Gibson, G.G. & Rostami-Hodjegan, A. Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitro-in vivo extrapolations (IVIVE). Xenobiotica 37, 1013-1014 (2007).
12. van der Greef, J. & McBurney, R.N. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov. 4, 961-967 (2005).
13. Preusch, P.C. Integrative and organ systems pharmacology: a new initiative from the National Institute of General Medical Sciences. Mol. Interv. 4, 72-73 (2004).
14. Atkinson, A.J. Jr & Lyster, P.M. Systems clinical pharmacology. Clin. Pharmacol. Ther. 88, 3-6 (2010).
15. Dollery, C.T. The challenge of complexity. Clin. Pharmacol. Ther. 88, 13-15 (2010).
16. Vicini, P. Multiscale modeling in drug discovery and development: future opportunities and present challenges. Clin. Pharmacol. Ther. 88, 126-129 (2010).
17. J amei, M., Dickinson, G.L. & Rostami-Hodjegan, A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down'recognition of covariates. Drug Metab. Pharmacokinet. 24, 53-75 (2009).
18. US Food and Drug Administration. Guidance for Industry - Drug Interaction Studies - Study Design, Data Analysis 〈http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362. pdf〉 (2012).
19. Rostami-Hodjegan, A., Tamai, I. & Pang, K.S. Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay! Biopharm. Drug Dispos. 33, 47-50 (2012).
20. J ohnson, T.N., Kerbusch, T., Jones, B., Tucker, G.T., Rostami-Hodjegan, A. & Milligan, P.A. Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power. Pharm. Stat. 8, 186-202 (2009).
21. Woodcock, J. Precompetitive research: a new prescription for drug development? Clin. Pharmacol. Ther. 87, 521-523 (2010).
22. Vieira, M.L. et al. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clin. Pharmacol. Ther. 91, 700-708 (2012).
23. Andersen, M.E. & Krewski, D. The vision of toxicity testing in the 21st century: moving from discussion to action. Toxicol. Sci. 117, 17-24 (2010).
24. Rostami-Hodjegan, A. & Tucker, G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6, 140-148 (2007).
25. J amei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G. & Rostami-Hodjegan, A. The Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 5, 211-223 (2009).
26. J amei, M. et al. Biosimulation in Biomedical Research, Healthcare and Drug Development (eds. Mosekilde, E., Sosnovtseva, O. & Rostami-Hodjegan, A.) 361-386 (Springer, New York, 2012).
27. J amei, M. et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 11, 225-237 (2009).
28. Pang, K.S. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab. Dispos. 31, 1507-1519 (2003).
29. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I. & Willingham, M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84, 7735-7738 (1987).
30. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E. & Zeldin, D.C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 34, 880-886 (2006).
31. Tukey, R.H. & Strassburg, C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40, 581-616 (2000).
32. Gibson, C.R., Bergman, A., Lu, P., Kesisoglou, F., Denney, W.S. & Mulrooney, E. Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling. Xenobiotica 39, 637-648 (2009).
33. Polak, S. et al. Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption. J. Pharm. Sci. (2012); e-pub ahead of print 19 April 2012.
34. Barter, Z.E. et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 8, 33-45 (2007).
35. Barter, Z.E., Chowdry, J.E., Harlow, J.R., Snawder, J.E., Lipscomb, J.C. & Rostami- Hodjegan, A. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab. Dispos. 36, 2405-2409 (2008).
36. Proctor, N.J., Tucker, G.T. & Rostami-Hodjegan, A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34, 151-178 (2004).
37. Almond, L.M., Yang, J., Jamei, M., Tucker, G.T. & Rostami-Hodjegan, A. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr. Drug Metab. 10, 420-432 (2009).
38. Yang, J. et al. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr. Drug Metab. 9, 384-394 (2008).
39. Dickinson, G.L., Lennard, M.S., Tucker, G.T. & Rostami-Hodjegan, A. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. Br. J. Clin. Pharmacol. 64, 14-26 (2007).
40. Dickinson, G.L., Rezaee, S., Proctor, N.J., Lennard, M.S., Tucker, G.T. & Rostami- Hodjegan, A. Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. J. Clin. Pharmacol. 47, 175-186 (2007).
41. J ohnson, T.N., Rostami-Hodjegan, A. & Tucker, G.T. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45, 931-956 (2006).
42. Inoue, S. et al. Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica 36, 499-513 (2006).
43. Chetty, M., Mattison, D. & Rostami-Hodjegan, A. Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. Curr. Drug Metab. (2012); e-pub ahead of print 22 March 2012.
44. Abduljalil, K., Furness, P., Johnson, T.N., Rostami-Hodjegan, A. & Soltani, H. Anatomical, Physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 51, 365-396 (2012).
45. Ghobadi, C. et al. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin. Pharmacokinet. 50, 809-822 (2011).
46. J ohnson, T.N., Boussery, K., Rowland-Yeo, K., Tucker, G.T. & Rostami-Hodjegan, A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 49, 189-206 (2010).
47. Tortorici, M.A. et al. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest. New Drugs 29, 1370-1380 (2011).
48. Rowland Yeo, K., Aarabi, M., Jamei, M. & Rostami-Hodjegan, A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev. Clin. Pharmacol. 4, 261-274 (2011).
49. Zhao, P. et al. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J. Clin. Pharmacol. 52, 91S-108S (2012).
50. Plowchalk, D.R. & Rowland Yeo, K. Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur. J. Clin. Pharmacol. (2012); e-pub ahead of print 19 J anuary 2012.
51. Rowland Yeo, K., Jamei, M., Yang, J., Tucker, G.T. & Rostami-Hodjegan, A. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci. 39, 298-309 (2010).
52. Langenfeld, E., Zanger, U.M., Jung, K., Meyer, H.E. & Marcus, K. Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics 9, 2313-2323 (2009).
53. Deo, A.K., Prasad, B., Balogh, L., Lai, Y. & Unadkat, J.D. Interindividual Variability in Hepatic Expression of the Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2): Quantification by Liquid Chromatography/Tandem Mass Spectrometry. Drug Metab. Dispos. 40, 852-855 (2012).
54. Li, N., Palandra, J., Nemirovskiy, O.V. & Lai, Y. LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species. Anal. Chem. 81, 2251-2259 (2009).
55. Ohtsuki, S. et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 40, 83-92 (2012).
56. Tucker, G.T. Measurement of the renal clearance of drugs. Br. J. Clin. Pharmacol. 12, 761-770 (1981).
57. Levy, G. Effect of plasma protein binding on renal clearance of drugs. J. Pharm. Sci. 69, 482-483 (1980).
58. Varma, M.V. et al. Physicochemical determinants of human renal clearance. J. Med. Chem. 52, 4844-4852 (2009).
59. Song, I.S. et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin. Pharmacol. Ther. 84, 559-562 (2008).
60. Urban, T.J. et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin. Pharmacol. Ther. 83, 416-421 (2008).
61. Ghibellini, G. et al. In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin. Pharmacol. Ther. 81, 406-413 (2007).
62. McNamara, P.J. & Alcorn, J. Protein binding predictions in infants. AAPS PharmSci 4, E4 (2002).
63. Berezhkovskiy, L.M. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J. Pharm. Sci. 93, 1628-1640 (2004).
64. Poulin, P. & Theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91, 129-156 (2002).
65. Rodgers, T. & Rowland, M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm. Res. 24, 918-933 (2007).
66. Barter, Z.E., Perrett, H.F., Yeo, K.R., Allorge, D., Lennard, M.S. & Rostami- Hodjegan, A. Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. Biopharm. Drug Dispos. 31, 516-532 (2010).
67. Ohtani, H., Barter, Z., Minematsu, T., Makuuchi, M., Sawada, Y. & Rostami- Hodjegan, A. Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharm. Drug Dispos. 32, 498-506 (2011).
68. Duan, J.Z., Jackson, A.J. & Zhao, P. Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach. J. Clin. Pharmacol. 51, 1087-1100 (2011).
69. Zhao, P. et al. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole -a simulation study. J. Clin. Pharmacol. 49, 351-359 (2009).
70. Leong, R. et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin. Pharmacol. Ther. 91, 926-931 (2012).
71. Buchwald, H. & Oien, D.M. Metabolic/bariatric surgery Worldwide 2008. Obes. Surg. 19, 1605-1611 (2009).
72. Darwich, A.S. et al. Trends in oral drug bioavailability following bariatric surgery: Examining the variable extent of impact on exposure of different drug classes. Br. J. Clin. Pharmacol. (2012); e-pub ahead of print 30 March 2012.
73. Skottheim, I.B. et al. Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. Clin. Pharmacol. Ther. 87, 699-705 (2010).
74. Skottheim, I.B. et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin. Pharmacol. Ther. 86, 311-318 (2009).
75. Darwich, A.S. et al. A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: Interplay between CYP3A gut wall metabolism, permeability and dissolution. J. Pharm. Pharmacol., (in press) (2012).
76. Rostami-Hodjegan, A. & Tucker, G. 'In silico' simulations to assess the 'in vivo'consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today Technol 1, 441-448 (2004).